IN8bio, Inc.
NASDAQ Global MarketTotal Valuation
IN8bio, Inc. carries a market capitalization of 7.14M, placing it among publicly traded companies globally. Its enterprise value stands at -5.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.14M |
| Enterprise Value | -5.71M |
Share Statistics
IN8bio, Inc. currently has 9.85M shares outstanding.
| Shares Outstanding | 9.85M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.09 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | -0.96 |
| P/OCF Ratio | -0.95 |
Financial Position
IN8bio, Inc. maintains a current ratio of 10.50, meaning it holds 10.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.50 |
| Quick Ratio | 10.17 |
| Debt / Equity | 10.33 |
| Debt / EBITDA | -0.14 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -82.28 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
IN8bio, Inc.'s stock has declined approximately -58.15217% over the past 52 weeks. The 50-day moving average sits at 1.53, while the 200-day moving average is 1.87.
| Beta (5Y) | N/A |
| 52-Week Price Change | -58.15217% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 1.87 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -17.13M, while operating income came in at -19.47M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -19.47M |
| Pretax Income | -18.98M |
| Net Income | -18.98M |
| EBITDA | -17.13M |
| EBIT | -19.47M |
| Earnings Per Share (EPS) | -2.02 |
Balance Sheet
IN8bio, Inc. holds 21.94M in cash and equivalents against 2.35M in total debt, resulting in a net debt position of -21.94M. Total book value stands at -146.18M, with working capital of 20.50M providing operational flexibility.
| Cash & Cash Equivalents | 21.94M |
| Total Debt | 2.35M |
| Net Debt | -21.94M |
| Equity (Book Value) | -146.18M |
| Book Value Per Share | -15.59 |
| Working Capital | 20.50M |
Cash Flow
IN8bio, Inc. produced -14.54M in operating cash flow over the past twelve months. After subtracting -9,000.00 in capital expenditures, free cash flow totaled -14.55M - equivalent to -1.55 per share.
| Operating Cash Flow | -14.54M |
| Capital Expenditures | -9,000.00 |
| Free Cash Flow | -14.55M |
| FCF Per Share | -1.55 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -176.94 |
| FCF Yield | -104.71 |
Stock Splits
IN8bio, Inc.'s most recent stock split took place on June 6, 2025 with a 30:1 split ratio.
| Last Split Date | 6/6/2025 |
| Split Ratio | 30:1 |
Scores
IN8bio, Inc. posts an Altman Z-Score of -6.91, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.91 |